

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No.: 91120000103100784F)

(Incorporated in People's Republic of China)

Resolutions Passed at the 6th Board Meeting for FY2016

The board of directors (the "Board") of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited collectively and individually accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "**Company**") had on 12 August 2016 duly convened its 6th Board Meeting for FY2016. The meeting was convened in compliance with the applicable Companies Law, Securities Law and the Memorandum & Articles of Association of the Company, and the following resolutions were discussed and passed by the by the 7 directors out of the full board of 9 directors, with Mr. Ma Gui Zhong and Mr. Zhang Jian Jin being absent.

1. That, the full text and summary of the second quarter and half yearly financial statement for FY 2016, prepared in accordance with the accounting standards of the People's Republic of China, and the second quarter and half yearly financial statement for FY 2016, prepared in accordance with the International Financial Reporting Standards be approved;
2. that the scheme of profit distribution policy of the Company for the first half of FY2016 be approved;

The Board proposed to declare a dividend of an aggregate amount of RMB76,887,307.60 on the basis of RMB1.0 (inclusive of taxes) for every 10 shares in the capital of the Company. The proposed dividend is payable in respect of 768,873,076 issued ordinary shares in the capital of the Company as at 30 June 2016.

3. that, "Report on the Deposit of Proceeds and the Use of Proceeds" (募集资金存放与实际使用情况的专项报告) be approved;
4. that, the appointment of Mr. Pan Qin as chief engineer of the Company be approved;

Mr. Pan Qin, born in June 1970, senior engineer, licensed pharmacist, graduated from Huaxi Medical University and China Pharmaceutical University with a bachelor degree of pharmacy, master degree of medicinal chemistry and PHD in medicinal chemistry (specializing in traditional Chinese medicinal chemistry). From July 1995 to June 2003, he worked with Tianjin Institute of Pharmaceutical Research holding positions of the research assistant of the pharmacology office, the research assistant of the planting office, the deputy director/deputy researcher of the information office, and the director of the modern Chinese medicine research office. From March 2008 to September 2008, he was the visiting scholar of Hong Kong University of Science and

Technology. He was appointed as the head of technology center of the Company since July 2003, deputy chief engineer of the Company since October 2008 and the assistant general manager of the Company since May 2013.

5. that the appointment of Ms. Yan Min as chief accountant of the Company be approved;

Ms. Yan Min, born in June 1969, senior accountant, bachelor degree, MBA. She was appointed as the manager of the finance department of the Company from December 2009 to May 2014, the deputy chief accountant and the manager of the finance department of the Company since May 2014, and the assistant general manager of the Company since November 2014.

6. that, the proposed convening of the first Extraordinary General Meeting in 2016 to seek shareholders' approval for, *inter alia*, resolution 2 above be approved.

By order of the Board

12 August 2016